Last reviewed · How we verify
ZP-Zolmitriptan
At a glance
| Generic name | ZP-Zolmitriptan |
|---|---|
| Sponsor | Zosano Pharma Corporation |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches (PHASE2, PHASE3)
- A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine (PHASE3)
- Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZP-Zolmitriptan CI brief — competitive landscape report
- ZP-Zolmitriptan updates RSS · CI watch RSS
- Zosano Pharma Corporation portfolio CI